Inovio Pharma (INO)
$9.81 0.44 (4.66%)
14:25 EST INO Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 891.99M
PE Ratio -8.60
Volume (Avg. Vol.) 16.40M
Day's Range 9.30 - 10.57
52-Week Range 3.14 - 33.79
Dividend & Yield N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
- From InvestorPlace
- From the Web
When will INO stock finally turn a corner? That's a question on some investor's minds, and recent data suggests a turnaround might be afoot.
Shares of INO stock is being held back by a delayed clinical trial for Inovio’s vaccine candidate to combat the coronavirus.
While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders.
By Joel Baglole
Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.
If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.
As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.
Is INO stock nothing more than a post-pandemic pop-and-drop story? Don't count Inovio out as a crucial funding source offers timely support.
Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?
INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.
The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.
Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase....
Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.
By Ian Cooper
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment. The world is in dire of need of a Covid-19 vaccine and the U.S. is engaged “Operation Warp Speed” to get a vaccine to market, but here's a regulator telling Inovio to pump the brakes.
INO stock is down but not out as the development of a Covid-19 vaccine is bound to have some bumps in the road.
It’s been a month since the FDA put Inovio’s Covid-19 vaccine on partial clinical hold. No news is definitely not good news for INO stock.
The FDA's latest decision has dealt a killer blow to INO stock, which was already struggling to keep up with Big Pharma in the vaccine race.
INO stock is in a rough spot of late, but it is poised to bounce back from these temporary setbacks with a strong product portfolio.
Navellier RatingsPowered by Portfolio Grader